Information updates

SCID Newborn Screening Update

The ASCIA Immunodeficiency Strategy was launched on 29 April 2022. ASCIA has worked in collaboration with patient organisations (IDFA, AusPips, IDFNZ and HAE Australasia), and other stakeholders to develop the Strategy. The first goal of the Strategy is to enable early diagnosis of severe combined immune deficiency (SCID) by newborn screening of the Australian population. 

Following the Strategy launch and long term advocacy by patient organisations and ASCIA members, ASCIA welcomes the formal recommendation for SCID to be included in Australian Newborn Bloodspot Screening Programs which was recently announced in a media statement by the Australian Government https://www.health.gov.au/ministers/the-hon-mark-butler-mp/media/international-neonatal-screening-day

It is a pleasure to announce that New South Wales has commenced routine SCID newborn screening as of 1st August 2022, and the Queensland state government has announced that they will fund routine SCID newborn screening. 

It is anticipated that other Australian states will also make funding commitments for SCID newborn screening.

The incidence of SCID is about 1 in 58,000 births. Most patients with SCID have a genetically identifiable cause, and usually develop severe, recurrent, persistent and opportunistic respiratory and gastrointestinal infections within the first few months of life, with failure to thrive. SCID is fatal in the first two years of life without early and definitive intervention which is enabled by newborn screening.

The ASCIA Immunodeficiency Strategy is available at https://www.nationalimmunodeficiencystrategy.org.au/

To read more about the Strategy launch go to https://www.allergy.org.au/about-ascia/info-updates/ascia-immunodeficiency-strategy-launch

This news item was issued on 4 July 2022 and updated on 1 August 2022 by Jill Smith, CEO of the Australasian Society of Clinical Immunology and Allergy (ASCIA). ASCIA is the peak professional body for clinical immunology and allergy in Australia and New Zealand.   

 

Mod ASCIA Member
Donate to AIFA
go to NAC website
About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia